SUCCESSFUL COST EFFECTIVE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS USING LOW DOSE VALGANCICLOVIR

被引：1
|
作者：
Halim, Medhat [1 ]
Alotaibi, Torki [1 ]
Gheith, Osama [2 ]
Adel, Hany [1 ]
Mosaad, Ahmed [1 ]
Abo-Atteya, Hassanein [1 ]
Zakareya, Zakareya [1 ]
Said, Tarek [1 ]
Nair, Prasad [1 ]
Nampoory, Naryanan [1 ]
机构：
[1] OTC, Nephrol, Kuwait, Kuwait
[2] MUNC, Nephrol, Kuwait, Kuwait
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2015年 / 30卷
关键词：
D O I：
10.1093/ndt/gfv185.54
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
FP865
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Valganciclovir for treatment of cytomegalovirus disease in kidney allograft recipients
    Lin, Hsin-Lin
    Tian, Yu-Feng
    Lee, Ling-Hsien
    Chu, Li-Ling
    Su, Hui-Chen
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 : S95 - S95
  • [32] IS THE VALACYCLOVIR PROPHYLAXIS EFFECTIVE FOR PREVENTION OF CYTOMEGALOVIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENTS?
    Park, Woo Yeong
    Yeo, Sang Mok
    Park, Hayeon
    Kang, Seong Sik
    Jin, Kyubok
    Park, Sung Bae
    Han, Seungyeup
    TRANSPLANT INTERNATIONAL, 2017, 30 : 490 - 490
  • [33] IS THE VALACYCLOVIR PROPHYLAXIS EFFECTIVE FOR PREVENTION OF CYTOMEGALOVIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENTS?
    Park, Woo Yeong
    Kang, Seong Sik
    Jin, Kyubok
    Park, Sung Bae
    Han, Seungyeup
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 418 - 418
  • [34] Ganciclovir Exposure under a 450 mg Daily Dosage of Valganciclovir for the Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients.
    Manuel, Oriol
    Pascual, Manuel
    Perrottet, Nancy
    Lamoth, Frederic
    Venetz, Jean-Pierre
    Decosterd, Laurent
    Buclin, Thierry
    Meylan, Pascal R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 249 - 249
  • [35] Short Course of Low Dose Valgancicolvir Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients
    Gopal, B.
    Sudhakar, G.
    Mohapatra, A.
    Abraham, A.
    Valson, A.
    Alexander, S.
    Jacob, S.
    Varughese, S.
    Jacob, C.
    Tamilarasi, V.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 259 - 260
  • [36] Short Course of Low Dose Valgancicolvir Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients
    Gopal, B.
    Sudhakar, G.
    Mohapatra, A.
    Abraham, A.
    Valson, A.
    Alexander, S.
    Jacob, S.
    Varughese, S.
    Jacob, C.
    Tamilarasi, V.
    TRANSPLANTATION, 2014, 98 : 259 - 260
  • [37] A retrospective analysis to evaluate the efficacy of valganciclovir versus ganciclovir for the prevention of cytomegalovirus disease in kidney and kidney-pancreas transplant recipients.
    Triemer, HL
    Heath, CM
    Smallwood, GA
    PHARMACOTHERAPY, 2005, 25 (10): : 1491 - 1491
  • [38] Effect of Low-Dose Vs Standard-Dose Valganciclovir in the Prevention of Cytomegalovirus Disease in Kidney Transplantation Recipients: A Systemic Review and Meta-Analysis
    Hwang, S. D.
    Lee, J. H.
    Lee, S. W.
    Kim, J. K.
    Kim, M. -J.
    Song, J. H.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (08) : 2473 - 2478
  • [39] Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients
    Clark, BS
    Chang, IF
    Karpen, SJ
    Herrera, L
    Scott, JD
    Bristow, LJ
    Quirós-Tejeira, RE
    Goss, JA
    TRANSPLANTATION, 2004, 77 (09) : 1480 - 1480
  • [40] Role of Secondary Prophylaxis With Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients
    Gardiner, Bradley J.
    Chow, Jennifer K.
    Price, Lori Lyn
    Nierenberg, Natalie E.
    Kent, David M.
    Snydman, David R.
    CLINICAL INFECTIOUS DISEASES, 2017, 65 (12) : 2000 - 2007
12345